What happened?Moderna shares (NASDAQ:MRNA), were up 3.7% as of Thursday morning's 11:45 AM EDT. Investors are expressing relief after the U.S. Food and Drug Administration (FDA), announced that it would add a warning label to Moderna's COVID-19 vaccination about the possibility of young adults and adolescents experiencing rare heart inflammation issues. Moderna's financial position is not likely to be affected by the FDA warning.What are you waiting for?Wednesday's meeting of the Centers for Disease Control and Prevention advisory committee focused on data regarding a possible link between messenger RNA vaccinations and cases of heart inflammation. Moderna stock fell more than 4% as investors worried about what the FDA and CDC might do to it.These fears were exaggerated. Moderna has no reason to believe that the new warning label will affect its chances of securing additional supply agreements for its vaccine.What now?Moderna's future is largely dependent on how new coronavirus varieties emerge. The spread of the more contagious Delta variant could be a positive for the company, as governments may have greater access to booster doses in the future.
